anthonyyazdaniml/CT-ADE-SOC huggingface dataset:
Intervention: Etelcalcetide
Trial phase: Phase 3
ATC code: H05BX04
SMILES: CC(=O)N[C@H](CSSC[C@H](N)C(=O)O)C(=O)N[C@H](C)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H](C)C(=O)N[C@H](CCCNC(=N)N)C(N)=O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 252
Group description: Participants received etelcalcetide administered by intravenous bolus injection at the end of each hemodialysis session TIW for 26 weeks.
Eligibility criteria:
Inclusion Criteria:

Subject understands the study procedures and agrees to participate in the study by giving written informed consent.
Subject is 18 years of age or older.
Subject agrees to not participate in another study of an investigational agent during the study.
Subject must be receiving hemodialysis 3 times weekly for at least 3 months
Other Inclusion Criteria may apply

Exclusion Criteria:

Currently receiving treatment in another investigational device or drug study, or ended treatment on another investigational device or drug study(s) within 8 weeks prior to screening.
Other investigational procedures while participating in this study are excluded.
Anticipated or scheduled parathyroidectomy during the study period.
Subject has received a parathyroidectomy within 3 months prior to dosing.
Anticipated or scheduled kidney transplant during the study period.
Subject has known sensitivity to any of the products or components to be administered during dosing.
Subject has participated in a prior clinical trial of AMG 416
Subject has an unstable medical condition based on medical history, physical examination, and routine laboratory tests, or is otherwise unstable in the judgment of the Investigator.
Subject has a history of any illness that, in the opinion of the Investigator, might confound the results of the study or pose additional risk to the subject.
Other Exclusion Criteria may apply
Intervention: Doxycycline
Trial phase: Phase 3
ATC code: A01AB22 | J01AA02 | J01AA20
SMILES: [H][C@@]12C(=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@]3([H])[C@H]1O)C(=O)c1c(O)cccc1[C@@H]2C
Sex: Female
Age groups: Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 10
Group description: Subjects randomized to receive doxycycline for a period of 12 weeks. A 12-week period thereafter will occur off study medication. The dose of doxycycline to be used in this study is 200mg/day in divided doses of 100mg twice daily. The dose of doxycycline being used in this study is 100mg because it is the standard approved dose.

doxycycline: 200mg/day in divided doses of 100mg twice daily
Eligibility criteria:
Inclusion Criteria:

Women between 18 and 40 years of age.
History of PCOS with < 8 periods the proceeding year
Clinical or biochemical evidence of androgen excess
BMI <40
Willingness to sign consent for study including participation with collection of blood specimens
Willingness to discontinue OCP for duration of study period up to 36 weeks

Exclusion Criteria:

Pregnancy
Hypersensitivity to doxycycline or tetracycline
History of Cushing's syndrome
History of hyperprolactinemia
History of congenital adrenal hyperplasia
Significant hepatic impairment, including serum AST or ALT >1.5 times upper limits of normal.
Significant renal impairment, GFR <60 ml/min
Current use of metformin, statins, glucocorticoids, spironolactone and/or anti-estrogens.
Intervention: Betamethasone
Trial phase: Not Applicable
ATC code: A01AC02 | A07EA04 | C05AA05 | C05AA09 | D07AB19 | D07AC01 | D07BC01 | D07CB04 | D07CC01 | D07XB05 | D07XC01 | D10AA03 | H02AB01 | H02AB02 | R01AD03 | R01AD06 | R01AD53 | R03BA04 | S01BA01 | S01BA06 | S01BB04 | S01CA01 | S01CA05 | S01CB01 | S01CB04 | S02BA06 | S02BA07 | S02CA06 | S03BA01 | S03BA03 | S03CA01 | S03CA06
SMILES: CC1CC2C3CCC4=CC(=O)C=CC4(C)C3(F)C(O)CC2(C)C1(O)C(=O)CO
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 3
Group description: Ozurdex (dexamethasone) 0.7 mg implant will be performed on Day 0. All patients will be evaluated monthly thereafter.

Intervention: One month following initial implantation/sham, patients will be evaluated for focal or grid laser treatment if the investigator feels the patient will benefit.

Re-implantation of Ozurdex (dexamethasone) may occur at any time > 3 months following last injection in group 1 if any of the following conditions are met:

Increase of > 50 microns from the best previous CRT measurement
Recurrence of intraretinal cystic edema
Persistent intraretinal cystic edema

Dexamethasone: Ozurdex (dexamethasone) 0.7mg steroid implant
Eligibility criteria:
Inclusion Criteria:

Adults> 18 years of age with type 1 or 2 diabetes mellitus
Patients with DME secondary to diabetes mellitus involving the center of the macula OCT thickness is > 300 microns with intraretinal cystic edema
BCVA between 20/40 to 20/400
Patient had vitrectomy surgery.
Provide a signed informed consent prior to any study procedure

Exclusion Criteria:

Patient unlikely to benefit from intravitreal Ozurdex due to macular ischemia, atrophy, or other condition
Patient with history of steroid response with IOP >35 mm Hg or requirement to be on > 2 glaucoma medications following previous steroid injection.
Previous injection of anti-VEGF or steroid in the study eye within 90 days
Vitrectomy, cataract surgery, or YAG capsulotomy within 90 days.
Current tractional detachment of the macula or vitreous hemorrhage obscuring details of the macula.
Pregnant, lactating females, or females of child-bearing potential that are not using reliable contraception.
Intervention: Betamethasone
Trial phase: Not Applicable
ATC code: A01AC02 | A07EA04 | C05AA05 | C05AA09 | D07AB19 | D07AC01 | D07BC01 | D07CB04 | D07CC01 | D07XB05 | D07XC01 | D10AA03 | H02AB01 | H02AB02 | R01AD03 | R01AD06 | R01AD53 | R03BA04 | S01BA01 | S01BA06 | S01BB04 | S01CA01 | S01CA05 | S01CB01 | S01CB04 | S02BA06 | S02BA07 | S02CA06 | S03BA01 | S03BA03 | S03CA01 | S03CA06
SMILES: CC1CC2C3CCC4=CC(=O)C=CC4(C)C3(F)C(O)CC2(C)C1(O)C(=O)CO
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 3
Group description: Ozurdex (dexamethasone) 0.7 mg implant will be performed on Day 0. All patients will be evaluated monthly thereafter.

Intervention: One month following initial implantation/sham, patients will be evaluated for focal or grid laser treatment if the investigator feels the patient will benefit.

Re-implantation of Ozurdex (dexamethasone) may occur at any time >6 months following last injection in group 2 if any of the following conditions are met:

Increase of > 50 microns from the best previous CRT measurement
Recurrence of intraretinal cystic edema
Persistent intraretinal cystic edema

Dexamethasone: Ozurdex (dexamethasone) 0.7mg steroid implant
Eligibility criteria:
Inclusion Criteria:

Adults> 18 years of age with type 1 or 2 diabetes mellitus
Patients with DME secondary to diabetes mellitus involving the center of the macula OCT thickness is > 300 microns with intraretinal cystic edema
BCVA between 20/40 to 20/400
Patient had vitrectomy surgery.
Provide a signed informed consent prior to any study procedure

Exclusion Criteria:

Patient unlikely to benefit from intravitreal Ozurdex due to macular ischemia, atrophy, or other condition
Patient with history of steroid response with IOP >35 mm Hg or requirement to be on > 2 glaucoma medications following previous steroid injection.
Previous injection of anti-VEGF or steroid in the study eye within 90 days
Vitrectomy, cataract surgery, or YAG capsulotomy within 90 days.
Current tractional detachment of the macula or vitreous hemorrhage obscuring details of the macula.
Pregnant, lactating females, or females of child-bearing potential that are not using reliable contraception.
Intervention: Betamethasone
Trial phase: Not Applicable
ATC code: A01AC02 | A07EA04 | C05AA05 | C05AA09 | D07AB19 | D07AC01 | D07BC01 | D07CB04 | D07CC01 | D07XB05 | D07XC01 | D10AA03 | H02AB01 | H02AB02 | R01AD03 | R01AD06 | R01AD53 | R03BA04 | S01BA01 | S01BA06 | S01BB04 | S01CA01 | S01CA05 | S01CB01 | S01CB04 | S02BA06 | S02BA07 | S02CA06 | S03BA01 | S03BA03 | S03CA01 | S03CA06
SMILES: CC1CC2C3CCC4=CC(=O)C=CC4(C)C3(F)C(O)CC2(C)C1(O)C(=O)CO
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 3
Group description: Sham Procedure will be performed on Day 0. All patients will be evaluated monthly thereafter.

Intervention: One month following initial implantation/sham, patients will be evaluated for focal or grid laser treatment if the investigator feels the patient will benefit. Also, at 13 months, patients in the sham group will be eligible for Ozurdex (dexamethasone) 0.7 mg implantation if initial inclusion/exclusion criteria are met. These patients would follow re-implantation guidelines of group 2.

Sham implantation may occur at any time > 6 months following last sham injection in group 3 if any of the following conditions are met:

Increase of > 50 microns from the best previous CRT measurement
Recurrence of intraretinal cystic edema
Persistent intraretinal cystic edema

Dexamethasone: Ozurdex (dexamethasone) 0.7mg steroid implant
Eligibility criteria:
Inclusion Criteria:

Adults> 18 years of age with type 1 or 2 diabetes mellitus
Patients with DME secondary to diabetes mellitus involving the center of the macula OCT thickness is > 300 microns with intraretinal cystic edema
BCVA between 20/40 to 20/400
Patient had vitrectomy surgery.
Provide a signed informed consent prior to any study procedure

Exclusion Criteria:

Patient unlikely to benefit from intravitreal Ozurdex due to macular ischemia, atrophy, or other condition
Patient with history of steroid response with IOP >35 mm Hg or requirement to be on > 2 glaucoma medications following previous steroid injection.
Previous injection of anti-VEGF or steroid in the study eye within 90 days
Vitrectomy, cataract surgery, or YAG capsulotomy within 90 days.
Current tractional detachment of the macula or vitreous hemorrhage obscuring details of the macula.
Pregnant, lactating females, or females of child-bearing potential that are not using reliable contraception.
Intervention: Tantalum
Trial phase: Phase 1 | Phase 2
SMILES: [Ta]
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 11
Group description: TRIESENCE® (triamcinolone acetonide injectable suspension 40 mg/mL) in a total volume of 100 uL administered via microneedle directly to the suprachoroidal space (SCS)

triamcinolone acetonide (Triesence®): 4 mg of TRIESENCE® (triamcinolone acetonide injectable suspension 40 mg/mL) administered as a single injection to the suprachoroidal space
Eligibility criteria:
Inclusion Criteria:

diagnosis of non-infectious intermediate, posterior or pan-uveitis

Exclusion Criteria:

any ocular trauma within the past 6 months in the study eye
any injection of intraocular corticosteroids or steroid implant or the Ozurdex® implant in the 6 months prior to the study treatment, or any prior use of Retisert™ in the study eye
any uncontrolled systemic disease that would preclude participation in the study or put the subject at risk due to study treatment or procedures
have a known HIV infection or other immunodeficiency disease for which corticosteroid therapy would be contraindicated
are monocular
have ocular hypertension
history of any intraocular surgery in the study eye
presence of an anterior staphyloma in the study eye
Intervention: Prasugrel
Trial phase: Phase 4
ATC code: B01AC22
SMILES: CC(=O)Oc1cc2c(s1)CCN(C(C(=O)C1CC1)c1ccccc1F)C2
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 24
Group description: Prasugrel oral loading dose of 60 mg administered preceding cardiac intervention

Prasugrel: Patients will be randomized to prasugrel or clopidogrel to assess the effect of these drugs on inhibition of platelet aggregation following the cessation of bivalirudin therapy.
Eligibility criteria:
Inclusion Criteria:

Signed informed consent before initiation of any study related procedures
Male or non-pregnant female aged 18 to ≤ 75 years
Referred for PCI or structural cardiac intervention and planned to receive bivalirudin treatment
Only subjects in whom the treating physician feels that clopidogrel and prasugrel are equivalent on the basis of available clinical literature will be included.

Exclusion Criteria:

Currently receiving glycoprotein IIb/IIIa inhibitors.
Have received prasugrel or clopidogrel within 2 weeks
Serum creatinine level >2.0
Hypersensitivity to bivalirudin, prasugrel, clopidogrel or aspirin
Currently on heparin administration or administered ≤ 4.5 h prior to intervention
Thrombocytopenia (<50,000/µL)
Severe systemic hypertension defined as systolic blood pressure >180 mm Hg and/or diastolic blood pressure >110 mm Hg
Body weight < 60 kg
Cardiogenic shock
Acute pericarditis
Active internal bleeding
History of bleeding diathesis within previous thirty days
Any history of intracranial hemorrhage, Transient ischemic attack (TIA ) or stroke
Arteriovenous malformations or aneurysms
Major surgical procedures or severe physical trauma within last thirty days.
Symptoms or findings suggestive of aortic dissection
Pregnancy
Participation in other clinical research studies involving the evaluation of investigational drugs or devices within 30 days of enrollment
Incompetent subjects or subjects otherwise unable to provide informed consent
Subjects in whom the treating physician believes that one agent (prasugrel or clopidogrel) is preferable over the other will be excluded from study participation.
Intervention: Clopidogrel
Trial phase: Phase 4
ATC code: B01AC04
SMILES: [H][C@@](C(=O)OC)(c1ccccc1Cl)N1CCc2sccc2C1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 24
Group description: Clopidogrel oral loading dose of 600 mg administered preceding cardiac intervention

Clopidogrel: Clopidogrel 600 mg as a loading dose immediately prior to the start of procedure and 75 mg daily thereafter
Eligibility criteria:
Inclusion Criteria:

Signed informed consent before initiation of any study related procedures
Male or non-pregnant female aged 18 to ≤ 75 years
Referred for PCI or structural cardiac intervention and planned to receive bivalirudin treatment
Only subjects in whom the treating physician feels that clopidogrel and prasugrel are equivalent on the basis of available clinical literature will be included.

Exclusion Criteria:

Currently receiving glycoprotein IIb/IIIa inhibitors.
Have received prasugrel or clopidogrel within 2 weeks
Serum creatinine level >2.0
Hypersensitivity to bivalirudin, prasugrel, clopidogrel or aspirin
Currently on heparin administration or administered ≤ 4.5 h prior to intervention
Thrombocytopenia (<50,000/µL)
Severe systemic hypertension defined as systolic blood pressure >180 mm Hg and/or diastolic blood pressure >110 mm Hg
Body weight < 60 kg
Cardiogenic shock
Acute pericarditis
Active internal bleeding
History of bleeding diathesis within previous thirty days
Any history of intracranial hemorrhage, Transient ischemic attack (TIA ) or stroke
Arteriovenous malformations or aneurysms
Major surgical procedures or severe physical trauma within last thirty days.
Symptoms or findings suggestive of aortic dissection
Pregnancy
Participation in other clinical research studies involving the evaluation of investigational drugs or devices within 30 days of enrollment
Incompetent subjects or subjects otherwise unable to provide informed consent
Subjects in whom the treating physician believes that one agent (prasugrel or clopidogrel) is preferable over the other will be excluded from study participation.
Intervention: Betamethasone
Trial phase: Phase 2 | Phase 3
ATC code: A01AC02 | A07EA04 | C05AA05 | C05AA09 | D07AB19 | D07AC01 | D07BC01 | D07CB04 | D07CC01 | D07XB05 | D07XC01 | D10AA03 | H02AB01 | H02AB02 | R01AD03 | R01AD06 | R01AD53 | R03BA04 | S01BA01 | S01BA06 | S01BB04 | S01CA01 | S01CA05 | S01CB01 | S01CB04 | S02BA06 | S02BA07 | S02CA06 | S03BA01 | S03BA03 | S03CA01 | S03CA06
SMILES: CC1CC2C3CCC4=CC(=O)C=CC4(C)C3(F)C(O)CC2(C)C1(O)C(=O)CO
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 17
Group description: Branch Retinal Vein Occlusion

dexamethasone implant
Eligibility criteria:
Inclusion Criteria:

Signed informed consent and authorization of use and disclosure of protected health information
Age more than or equal to 18 years
Diagnosis of macular edema due to central or branch retinal vein occlusion
Intraretinal or subretinal fluid in the macula determined by Spectralis OCT
Best corrected visual acuity score in the study eye of 20/30 to 20/400 inclusive (Snellen equivalents using the ETDRS protocol at a distance of 4 meters)
In the opinion of the investigator, decreased vision in the study eye is due to foveal thickening from vein occlusion and not from other obvious causes of decreased vision
Persistent or recurrent edema despite prolonged treatment with an anti-VEFG agent

Exclusion Criteria:

Scatter laser photocoagulation or macular photocoagulation within 3 months of study entry in the study eye
Intraocular surgery in the study eye within 3 months of study entry
Use of intraocular or periocular injection of steroids in the study eye (e.g., triamcinolone) within 4 months of study entry
Previous use of an anti-VEGF drug within 1 month of study entry
Yttrium-Aluminum-Garnet (YAG) laser capsulotomy within 1 month of study entry
Any condition that the investigator believes would pose a significant hazard to the subject if investigational therapy were initiated.
Inability to comply with study or follow up procedures
History of glaucoma or documented history of steroid-induced glaucoma.
Patients with active or suspected ocular or periocular infection, including most viral diseases of the cornea and conjunctiva, including active epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, varicella, mycobacterial infections, and fungal diseases.
Aphakic eyes with rupture of the posterior lens capsule.
Eyes with ACIOL and rupture of the posterior lens capsule.
Patients with hypersensitivity to dexamethasone or to any other components of the product
Intervention: Inositol
Trial phase: Phase 2
ATC code: A11HA07
SMILES: O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@H]1O
Sex: All
Age groups: Adult
Healthy volunteers: No
Participants at risk: 12
Group description: ELND005 250 mg BID

ELND005
Eligibility criteria:
Inclusion Criteria:

18 - 45 years of age
Has an IQ of > 40 (K-BIT)
Able and willing to have a brain MRI

Exclusion Criteria:

Symptoms of dementia or worsening cognition over the past year.
Has a history of hepatitis B, hepatitis C, or HIV
Intervention: Nicotine
Trial phase: Not Applicable
ATC code: N07BA01
SMILES: CN1CCCC1c1cccnc1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 164
Group description: Patients receiving a free months supply of nicotine
Eligibility criteria:
Inclusion Criteria:

Hospitalized patients with a Cardiopulmonary admission.

Exclusion Criteria:

Terminal illness, history of Serious Psychiatric illness or substance abuse, Pregnancy, Cognitive or language barriers.
Intervention: ARSENIC TRIOXIDE
Trial phase: Phase 1 | Phase 2
ATC code: L01XX27
SMILES: O=[As]O[As]=O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 5
Group description: Patients receive arsenic trioxide IV over 2 hours on days 1-5. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.

arsenic trioxide: Given IV
Eligibility criteria:
INCLUSION CRITERIA

Basal cell carcinoma (BCC)
Ineligible for curative locoregional treatment and have either progressed on, did not tolerate, unwilling to try or ineligible for investigational smoothened antagonist such as vismodegib (GDC 0449), XL 139 (BMS 833923), IPI- 926, LDE225 and PF-04449913
Life expectancy estimate > 3 months
Performance status Eastern Cooperative Oncology Group (ECOG) 0-2
Absolute neutrophil count ≥ 1,500/mcL
Platelets ≥ 100,000/mcL
Total bilirubin within normal institutional limits
Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) ≤ 2.5 x institutional upper limit of normal
Creatinine within normal institutional limits
Corrected QT interval (QTC) by 12 lead electrocardiogram (EKG) < 450 msecs
Serum potassium within normal limits
Magnesium within normal limits
Calcium within normal limits
Ability to understand and the willingness to sign a written informed consent document
Evaluable tumor and be potentially eligible for pre and post ATO tumor biopsy
Receiving potassium wasting diuretics or amphotericin, while not excluded, must be noted to have theoretically increased arrhythmia risks with ATO

EXCLUSION CRITERIA

Concurrent use of other Investigational agents
Cardiac arrhythmias
Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, recurrent seizure history or psychiatric illness/social situations that would limit compliance with study requirements
Pregnant or lactating
Intervention: Minocycline
Trial phase: Phase 2
ATC code: A01AB23 | D10AF07 | J01AA08 | J01AA20
SMILES: [H][C@@]12Cc3c(N(C)C)ccc(O)c3C(=O)C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@]1([H])C2
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 33
Group description: Minocycline 100 mg (capsule) two times a day to begin with start of maintenance therapy (3 months +/- 2 days)
Eligibility criteria:
Inclusion Criteria:

Patients with pathologically diagnosed who have received induction chemotherapy, with or without AuSCT, and who have qualified to receive lenalidomide-based maintenance therapy for their MM.
Patients > or = 18 years old.
Patients able to render informed consent and to follow protocol requirements.
Patients who speak English (due to patient-reported outcome language options, we are only accruing English-speaking patients to the protocol).
Patients with normal renal function according to MD Anderson testing standards and no prior renal disease [screening cut off for serum creatinine < 1.5 times the upper limit of normal].
Patients with normal hepatic function according to MD Anderson testing standards and no prior liver disease [screening results for total bilirubin must be < 1.5 times the upper limit of normal; screening results for alkaline phosphatase (ALP) and alanine aminotransferase (ALT) must be < 2 times the upper limit of normal; if available, screening results for aspartate aminotransferase (AST) must be < 2 times the upper limit of normal].

Exclusion Criteria:

Patients who are taking minocycline for other conditions, as determined by the treating physician
Patients with hypersensitivity to tetracyclines
Women who are pregnant or nursing; pregnancy will be confirmed by urine test
Patients who are enrolled in other clinical trials that have symptom management as primary outcome
Patients who are not able to use telephone-based interactive voice response software due to physical limitations (e.g., impaired hearing)
Patients taking any tetracycline in the last 15 days
Patients on Vitamin K antagonist warfarin